| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2406377 | Vaccine | 2008 | 7 Pages |
Abstract
SummaryNew Zealand introduced a tailor-made vaccine (MeNZB™) for epidemic control of Group B meningococcal disease. The Intensives Vaccine Monitoring Programme (IVMP), which prospectively collected data electronically on a cohort of children receiving vaccinations in sentinel practices across NZ, was developed as part of a national multi-faceted safety strategy. The main aim of the IVMP was to identify the presence of unexpected adverse events occurring with MeNZB™ vaccination. We describe the methodology and success factors plus consider the limitations encountered in this system which shows potential as a means for post-marketing vaccine and medicine surveillance in the future.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Michael V. Tatley, Desireé L. Kunac, Anne McNicholas, Lifeng Zhou, Suzie Ballantyne, Janelle Ashton, Paul Stehr-Green, Yvonne Galloway, Stewart Reid,